"Do we all not believe that the 25/50 dose is more to support the endo trial safety wise?"
i think its to support all chronic indications, since uterine thickening seems to be inversely related to dose, and too thick an endometrium, as i said previously, can hurt the drug's chances because of the need for a tissue diagnosis
a thicker endometrium is also likely to be associated with a heavier withdrawal menses, which is both intuitive and has been my experience clinically
efficacy of course also is likely to be better - certainly for endo, and perhaps also for fibroids
"Think hard here dewo"
I'm trying! I am sure shorts have consulted with their clinical people* before placing their bet, so take what i say for what its worth - just one opinion from a clinician, who may well be biased because he owns stock
"But doesn't the anemia trial seam a little odd. Like they are really just collecting safety data points and it's not going to an NDA?"
absolutely not - remember rprx really isn't even blazing a new path here - lupron has a 3 month label for fibroids in the preoperative setting.
*side note - about a year ago i had dinner with an old friend from residency. i forget how it came up but he mentioned he recently got a nice check from a fund to discuss some drug candidate - proellex. he had never heard of it, and shortly after speaking to the fund went and bought some shares. I told him i was a shareholder as well
Market Data 
Markets 
AI
